| Description |
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). |
| Synonyms |
Epivir; Zeffix; Heptovir; Epivir-HBV |
| IUPAC Name |
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| Molecular Weight |
229.26 |
| Molecular Formula |
C8H11N3O3S |
| InChI |
JTEGQNOMFQHVDC-NKWVEPMBSA-N |
| InChI Key |
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1 |
| Drug Categories |
Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals used in combination for the treatment of HIV infections; BCRP/ABCG2 Substrates; Deoxycytidine; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; OCT1 substrates; OCT2 Substrates; P-glycoprotein substrates; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors |
| Drug Interactions |
Abemaciclib-Abemaciclib may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Aceclofenac-Aceclofenac may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Acemetacin-Acemetacin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Acetaminophen-Acetaminophen may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Acetazolamide-Acetazolamide may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy. |
| Half-Life |
5 to 7 hours (healthy or HBV-infected patients) |
| Isomeric SMILES |
C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N |
| Therapeutic Category |
Antivirals |
| Type |
Small Molecule |
